The fluorescence in situ hybridization (FISH) is the gold standard in human epidermal growth factor receptor 2 (HER2) status assessment in breast cancer. The dissemination of the technique is impeded by the cost of reagents and long experimental time. For overcoming these limitations, we have developed a new method for implementing FISH for HER2 assessment for tissue analysis based on microfluidic technology.